Drug Evaluation Committee RMP training slides for MRs (revised August 2025)
Pharmacovigilance Subcommittee
October 2025
Japan Pharmaceutical Manufacturers Association, Committee on Drug Evaluation
Pharmacovigilance Subcommittee, Continuing Issues Response Team 1 (KT1)
Aiming at the development of a system for drug risk management plans, the Team for Addressing Ongoing Issues of the PV Subcommittee of the Drug Evaluation Committee has so far published "RMP Training Slides for MRs" and "RMP Explanation Slides by MRs (slide template for RMP explanation for medical institutions)" in March, 2025.
More than 10 years have passed since the system of drug risk management plans (RMPs) came into effect in Japan, and surveys have shown that pharmacists' recognition and utilization of RMPs have also progressed. On the other hand, there are some cases where MRs are promoting drugs with little regard for side effects and safety.
The Pharmaceutical Manufacturers Association of Japan (PMAJ) Code of Practice was revised in May 2025, and the code clearly states that MRs are required to acquire knowledge and provide appropriate information to medical professionals not only for electronic dossiers but also for RMPs.
We have revised the "RMP Training Slides for MRs" to help them understand the importance of providing information based on RMPs to healthcare professionals, including the above. We hope that the effective use of these slides by pharmaceutical companies will further promote the provision of RMP-based information by MRs to healthcare professionals.
Deliverables of the Drug Evaluation Committee Return to list of all deliverables